Holen Sie sich die Stockscreener-App
3.14
1.26%
-0.04
Schlusskurs vom Vortag:
$3.18
Offen:
$3.17
24-Stunden-Volumen:
637.16K
Relative Volume:
0.64
Marktkapitalisierung:
$369.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-238.77M
KGV:
-0.1171
EPS:
-26.808
Netto-Cashflow:
$-216.62M
1W Leistung:
-12.53%
1M Leistung:
-29.60%
6M Leistung:
-62.57%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.10
$3.2685
1-Wochen-Bereich:
$3.10
$3.70
52-Wochen-Spanne:
$3.10
$13.50
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
3.14 | 369.79M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
(ALMS) Trading Advice - news.stocktradersdaily.com
Guggenheim raises Alumis stock to buy with $18 price target By Investing.com - Investing.com Canada
Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Guggenheim - Defense World
Alumis (ALMS) Projected to Post Quarterly Earnings on Wednesday - Defense World
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
Alumis resumed with a Buy at Guggenheim - TipRanks
Guggenheim raises Alumis stock to buy with $18 price target - Investing.com India
Traders Purchase High Volume of Put Options on Alumis (NASDAQ:ALMS) - Defense World
Alumis resumed with an Overweight at Morgan Stanley - TipRanks
Alumis to Present at the Jefferies Global Healthcare Investor Conference - The Manila Times
AyurMaya Capital Management's Strategic Acquisition in Alumis Inc - GuruFocus
Alumis CEO to Share Late-Stage Immune Disease Pipeline Updates at Jefferies Healthcare Conference - Stock Titan
News Flash: Analysts Just Made A Substantial Upgrade To Their Alumis Inc. (NASDAQ:ALMS) Forecasts - simplywall.st
Alumis completes enrollment of Phase 3 ONWARD program of ESK-001 - TipRanks
Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis - Nasdaq
Alumis Advances Game-Changing Oral Psoriasis Drug: 1,700 Patients Enrolled in Phase 3 Trial - Stock Titan
Largest borrow rate increases among liquid names - TipRanks
FY2026 Earnings Forecast for Alumis Issued By HC Wainwright - Defense World
Alumis completes merger with ACELYRIN, extends cash runway By Investing.com - Investing.com Canada
Alumis completes merger with ACELYRIN, extends cash runway - Investing.com Australia
Alumis Completes Merger With ACELYRIN, Strengthens Pipeline And Cash Runway - Nasdaq
Alumis, Acelyrin Close Merger - marketscreener.com
Alumis Inc. Completes Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Completes Merger and Delists from Nasdaq - TipRanks
Alumis Inc. Completes Merger with ACELYRIN, Inc. to Strengthen Pipeline in Immune-Mediated Disease Therapies - Nasdaq
Alumis completes merger with Acelyrin - TipRanks
Alumis Completes Merger with ACELYRIN - TradingView
Alumis-ACELYRIN Merger Creates Powerhouse in Immune Disease Drug Development with 2027 Cash Runway - Stock Titan
ACELYRIN Stockholders Approve Merger with Alumis - TipRanks
Alumis Inc. Stockholders Approve Merger with ACELYRIN - TipRanks
How To Trade (ALMS) - news.stocktradersdaily.com
Alumis Inc. Reports Q1 2025 Financial Results and Strategic Progress - TipRanks
Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating - marketscreener.com
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView
Earnings Flash (ALMS) ALUMIS INC. Reports Q1 Revenue $17.4M - marketscreener.com
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - The Manila Times
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India
Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India
Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com
Alumis Stockholders Approve Merger with ACELYRIN - The Manila Times
Alumis wins shareholder nod for ACELYRIN merger - Investing.com
ACELYRIN shareholders approve Alumis merger deal - Investing.com
Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq
Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider
ACELYRIN-Alumis Merger Gets Green Light: New Powerhouse in Immune Disease Treatment Emerges - Stock Titan
Barclays PLC Has $193,000 Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - Defense World
Mariner LLC Buys Shares of 18,122 Alumis Inc. (NASDAQ:ALMS) - Defense World
(ALMS) On The My Stocks Page - news.stocktradersdaily.com
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):